nodes	percent_of_prediction	percent_of_DWPC	metapath
Neostigmine—ABCB1—colon cancer	0.459	1	CbGaD
Neostigmine—ACHE—Irinotecan—colon cancer	0.233	0.508	CbGbCtD
Neostigmine—BCHE—Irinotecan—colon cancer	0.14	0.306	CbGbCtD
Neostigmine—ABCB1—Irinotecan—colon cancer	0.0356	0.0776	CbGbCtD
Neostigmine—ABCB1—Vincristine—colon cancer	0.0311	0.0678	CbGbCtD
Neostigmine—ABCB1—Methotrexate—colon cancer	0.0188	0.0411	CbGbCtD
Neostigmine—Post procedural complication—Capecitabine—colon cancer	0.00693	0.0841	CcSEcCtD
Neostigmine—Salivation—Irinotecan—colon cancer	0.00252	0.0306	CcSEcCtD
Neostigmine—Miosis—Irinotecan—colon cancer	0.00234	0.0284	CcSEcCtD
Neostigmine—Slurred speech—Fluorouracil—colon cancer	0.00209	0.0254	CcSEcCtD
Neostigmine—Lacrimation—Irinotecan—colon cancer	0.00166	0.0201	CcSEcCtD
Neostigmine—Lacrimation—Fluorouracil—colon cancer	0.00159	0.0193	CcSEcCtD
Neostigmine—Abdominal cramps—Vincristine—colon cancer	0.00149	0.018	CcSEcCtD
Neostigmine—Abdominal cramps—Irinotecan—colon cancer	0.00145	0.0175	CcSEcCtD
Neostigmine—Paralysis—Vincristine—colon cancer	0.00144	0.0175	CcSEcCtD
Neostigmine—Nystagmus—Vincristine—colon cancer	0.0014	0.017	CcSEcCtD
Neostigmine—Chest tightness—Capecitabine—colon cancer	0.00139	0.0169	CcSEcCtD
Neostigmine—Nystagmus—Fluorouracil—colon cancer	0.00131	0.0159	CcSEcCtD
Neostigmine—Lacrimation increased—Irinotecan—colon cancer	0.00106	0.0129	CcSEcCtD
Neostigmine—Dysarthria—Irinotecan—colon cancer	0.00103	0.0125	CcSEcCtD
Neostigmine—Lacrimation increased—Fluorouracil—colon cancer	0.00102	0.0123	CcSEcCtD
Neostigmine—Dysarthria—Fluorouracil—colon cancer	0.000989	0.012	CcSEcCtD
Neostigmine—Pharyngolaryngeal pain—Capecitabine—colon cancer	0.000968	0.0117	CcSEcCtD
Neostigmine—Laryngeal pain—Capecitabine—colon cancer	0.000959	0.0116	CcSEcCtD
Neostigmine—Salivary hypersecretion—Irinotecan—colon cancer	0.000949	0.0115	CcSEcCtD
Neostigmine—Coma—Vincristine—colon cancer	0.000916	0.0111	CcSEcCtD
Neostigmine—Coma—Fluorouracil—colon cancer	0.000855	0.0104	CcSEcCtD
Neostigmine—Chest discomfort—Capecitabine—colon cancer	0.000739	0.00896	CcSEcCtD
Neostigmine—Lacrimation increased—Capecitabine—colon cancer	0.000709	0.0086	CcSEcCtD
Neostigmine—Osteoarthritis—Irinotecan—colon cancer	0.000709	0.0086	CcSEcCtD
Neostigmine—Paralysis—Methotrexate—colon cancer	0.0007	0.0085	CcSEcCtD
Neostigmine—Cardiac arrest—Vincristine—colon cancer	0.000692	0.0084	CcSEcCtD
Neostigmine—Dysarthria—Capecitabine—colon cancer	0.000691	0.00838	CcSEcCtD
Neostigmine—Osteoarthritis—Fluorouracil—colon cancer	0.000679	0.00824	CcSEcCtD
Neostigmine—Cardiac arrest—Irinotecan—colon cancer	0.000674	0.00818	CcSEcCtD
Neostigmine—Cardiac arrest—Fluorouracil—colon cancer	0.000646	0.00783	CcSEcCtD
Neostigmine—Cramp muscle—Irinotecan—colon cancer	0.000638	0.00774	CcSEcCtD
Neostigmine—Urinary incontinence—Capecitabine—colon cancer	0.000631	0.00766	CcSEcCtD
Neostigmine—Sweating increased—Irinotecan—colon cancer	0.000597	0.00724	CcSEcCtD
Neostigmine—Dysarthria—Methotrexate—colon cancer	0.000514	0.00624	CcSEcCtD
Neostigmine—Bradycardia—Irinotecan—colon cancer	0.000499	0.00606	CcSEcCtD
Neostigmine—Urinary tract disorder—Vincristine—colon cancer	0.000497	0.00603	CcSEcCtD
Neostigmine—Connective tissue disorder—Vincristine—colon cancer	0.000495	0.006	CcSEcCtD
Neostigmine—Urethral disorder—Vincristine—colon cancer	0.000494	0.00599	CcSEcCtD
Neostigmine—Connective tissue disorder—Irinotecan—colon cancer	0.000482	0.00585	CcSEcCtD
Neostigmine—Osteoarthritis—Capecitabine—colon cancer	0.000475	0.00576	CcSEcCtD
Neostigmine—Flushing—Irinotecan—colon cancer	0.000455	0.00552	CcSEcCtD
Neostigmine—Mediastinal disorder—Vincristine—colon cancer	0.000454	0.00551	CcSEcCtD
Neostigmine—Cardiac arrest—Capecitabine—colon cancer	0.000451	0.00547	CcSEcCtD
Neostigmine—Coma—Methotrexate—colon cancer	0.000445	0.00539	CcSEcCtD
Neostigmine—Mediastinal disorder—Irinotecan—colon cancer	0.000442	0.00536	CcSEcCtD
Neostigmine—Mental disorder—Vincristine—colon cancer	0.000441	0.00535	CcSEcCtD
Neostigmine—Arrhythmia—Irinotecan—colon cancer	0.000438	0.00531	CcSEcCtD
Neostigmine—Flatulence—Irinotecan—colon cancer	0.000421	0.0051	CcSEcCtD
Neostigmine—Arrhythmia—Fluorouracil—colon cancer	0.00042	0.00509	CcSEcCtD
Neostigmine—Muscle spasms—Irinotecan—colon cancer	0.000411	0.00498	CcSEcCtD
Neostigmine—Bronchospasm—Capecitabine—colon cancer	0.000403	0.00489	CcSEcCtD
Neostigmine—Agitation—Vincristine—colon cancer	0.000403	0.00489	CcSEcCtD
Neostigmine—Sweating increased—Capecitabine—colon cancer	0.0004	0.00485	CcSEcCtD
Neostigmine—Syncope—Irinotecan—colon cancer	0.000383	0.00464	CcSEcCtD
Neostigmine—Convulsion—Vincristine—colon cancer	0.00038	0.00461	CcSEcCtD
Neostigmine—Loss of consciousness—Irinotecan—colon cancer	0.000375	0.00455	CcSEcCtD
Neostigmine—Anaphylactic shock—Vincristine—colon cancer	0.000358	0.00434	CcSEcCtD
Neostigmine—Convulsion—Fluorouracil—colon cancer	0.000354	0.0043	CcSEcCtD
Neostigmine—Osteoarthritis—Methotrexate—colon cancer	0.000353	0.00428	CcSEcCtD
Neostigmine—Nervous system disorder—Vincristine—colon cancer	0.000351	0.00426	CcSEcCtD
Neostigmine—Anaphylactic shock—Irinotecan—colon cancer	0.000348	0.00423	CcSEcCtD
Neostigmine—Hyperhidrosis—Vincristine—colon cancer	0.000346	0.0042	CcSEcCtD
Neostigmine—Shock—Irinotecan—colon cancer	0.000343	0.00416	CcSEcCtD
Neostigmine—Nervous system disorder—Irinotecan—colon cancer	0.000342	0.00414	CcSEcCtD
Neostigmine—Hyperhidrosis—Irinotecan—colon cancer	0.000337	0.00409	CcSEcCtD
Neostigmine—Hypotension—Vincristine—colon cancer	0.000334	0.00406	CcSEcCtD
Neostigmine—Bradycardia—Capecitabine—colon cancer	0.000334	0.00405	CcSEcCtD
Neostigmine—Anaphylactic shock—Fluorouracil—colon cancer	0.000334	0.00405	CcSEcCtD
Neostigmine—Nervous system disorder—Fluorouracil—colon cancer	0.000327	0.00397	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Vincristine—colon cancer	0.000326	0.00395	CcSEcCtD
Neostigmine—Tachycardia—Fluorouracil—colon cancer	0.000326	0.00395	CcSEcCtD
Neostigmine—Hypotension—Irinotecan—colon cancer	0.000326	0.00395	CcSEcCtD
Neostigmine—Urinary tract disorder—Capecitabine—colon cancer	0.000324	0.00393	CcSEcCtD
Neostigmine—Insomnia—Vincristine—colon cancer	0.000324	0.00393	CcSEcCtD
Neostigmine—Connective tissue disorder—Capecitabine—colon cancer	0.000323	0.00391	CcSEcCtD
Neostigmine—Urethral disorder—Capecitabine—colon cancer	0.000322	0.0039	CcSEcCtD
Neostigmine—Insomnia—Irinotecan—colon cancer	0.000315	0.00382	CcSEcCtD
Neostigmine—Hypotension—Fluorouracil—colon cancer	0.000312	0.00378	CcSEcCtD
Neostigmine—Dyspnoea—Irinotecan—colon cancer	0.000311	0.00377	CcSEcCtD
Neostigmine—Somnolence—Irinotecan—colon cancer	0.00031	0.00376	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Vincristine—colon cancer	0.000309	0.00375	CcSEcCtD
Neostigmine—Flushing—Capecitabine—colon cancer	0.000305	0.0037	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000304	0.00369	CcSEcCtD
Neostigmine—Insomnia—Fluorouracil—colon cancer	0.000302	0.00366	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Irinotecan—colon cancer	0.000301	0.00365	CcSEcCtD
Neostigmine—Dyspnoea—Fluorouracil—colon cancer	0.000298	0.00361	CcSEcCtD
Neostigmine—Somnolence—Fluorouracil—colon cancer	0.000297	0.0036	CcSEcCtD
Neostigmine—Mediastinal disorder—Capecitabine—colon cancer	0.000296	0.00359	CcSEcCtD
Neostigmine—Arrhythmia—Capecitabine—colon cancer	0.000293	0.00356	CcSEcCtD
Neostigmine—Gastrointestinal pain—Vincristine—colon cancer	0.000293	0.00355	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000288	0.00349	CcSEcCtD
Neostigmine—Mental disorder—Capecitabine—colon cancer	0.000288	0.00349	CcSEcCtD
Neostigmine—Gastrointestinal pain—Irinotecan—colon cancer	0.000285	0.00346	CcSEcCtD
Neostigmine—Abdominal pain—Vincristine—colon cancer	0.000283	0.00343	CcSEcCtD
Neostigmine—Flatulence—Capecitabine—colon cancer	0.000282	0.00342	CcSEcCtD
Neostigmine—Abdominal pain—Irinotecan—colon cancer	0.000275	0.00334	CcSEcCtD
Neostigmine—Muscle spasms—Capecitabine—colon cancer	0.000275	0.00333	CcSEcCtD
Neostigmine—Drowsiness—Methotrexate—colon cancer	0.000272	0.0033	CcSEcCtD
Neostigmine—Urticaria—Fluorouracil—colon cancer	0.000265	0.00322	CcSEcCtD
Neostigmine—Hypersensitivity—Vincristine—colon cancer	0.000264	0.0032	CcSEcCtD
Neostigmine—Hypersensitivity—Irinotecan—colon cancer	0.000257	0.00311	CcSEcCtD
Neostigmine—Asthenia—Vincristine—colon cancer	0.000257	0.00311	CcSEcCtD
Neostigmine—Syncope—Capecitabine—colon cancer	0.000256	0.00311	CcSEcCtD
Neostigmine—Loss of consciousness—Capecitabine—colon cancer	0.000251	0.00305	CcSEcCtD
Neostigmine—Asthenia—Irinotecan—colon cancer	0.00025	0.00303	CcSEcCtD
Neostigmine—Hypersensitivity—Fluorouracil—colon cancer	0.000246	0.00298	CcSEcCtD
Neostigmine—Diarrhoea—Vincristine—colon cancer	0.000245	0.00297	CcSEcCtD
Neostigmine—Arthralgia—Capecitabine—colon cancer	0.000243	0.00295	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000242	0.00293	CcSEcCtD
Neostigmine—Urinary tract disorder—Methotrexate—colon cancer	0.000241	0.00293	CcSEcCtD
Neostigmine—Urethral disorder—Methotrexate—colon cancer	0.00024	0.00291	CcSEcCtD
Neostigmine—Diarrhoea—Irinotecan—colon cancer	0.000238	0.00289	CcSEcCtD
Neostigmine—Dry mouth—Capecitabine—colon cancer	0.000238	0.00289	CcSEcCtD
Neostigmine—Dizziness—Vincristine—colon cancer	0.000237	0.00287	CcSEcCtD
Neostigmine—Pruritus—Fluorouracil—colon cancer	0.000236	0.00286	CcSEcCtD
Neostigmine—Dizziness—Irinotecan—colon cancer	0.00023	0.00279	CcSEcCtD
Neostigmine—Shock—Capecitabine—colon cancer	0.000229	0.00278	CcSEcCtD
Neostigmine—Nervous system disorder—Capecitabine—colon cancer	0.000229	0.00277	CcSEcCtD
Neostigmine—Diarrhoea—Fluorouracil—colon cancer	0.000228	0.00277	CcSEcCtD
Neostigmine—Tachycardia—Capecitabine—colon cancer	0.000228	0.00276	CcSEcCtD
Neostigmine—Vomiting—Vincristine—colon cancer	0.000228	0.00276	CcSEcCtD
Neostigmine—Skin disorder—Capecitabine—colon cancer	0.000227	0.00275	CcSEcCtD
Neostigmine—Rash—Vincristine—colon cancer	0.000226	0.00274	CcSEcCtD
Neostigmine—Hyperhidrosis—Capecitabine—colon cancer	0.000225	0.00273	CcSEcCtD
Neostigmine—Dermatitis—Vincristine—colon cancer	0.000225	0.00273	CcSEcCtD
Neostigmine—Headache—Vincristine—colon cancer	0.000224	0.00272	CcSEcCtD
Neostigmine—Vomiting—Irinotecan—colon cancer	0.000222	0.00269	CcSEcCtD
Neostigmine—Dizziness—Fluorouracil—colon cancer	0.000221	0.00268	CcSEcCtD
Neostigmine—Mediastinal disorder—Methotrexate—colon cancer	0.00022	0.00267	CcSEcCtD
Neostigmine—Rash—Irinotecan—colon cancer	0.00022	0.00266	CcSEcCtD
Neostigmine—Dermatitis—Irinotecan—colon cancer	0.00022	0.00266	CcSEcCtD
Neostigmine—Headache—Irinotecan—colon cancer	0.000218	0.00265	CcSEcCtD
Neostigmine—Hypotension—Capecitabine—colon cancer	0.000218	0.00264	CcSEcCtD
Neostigmine—Mental disorder—Methotrexate—colon cancer	0.000214	0.0026	CcSEcCtD
Neostigmine—Nausea—Vincristine—colon cancer	0.000213	0.00258	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000212	0.00258	CcSEcCtD
Neostigmine—Vomiting—Fluorouracil—colon cancer	0.000212	0.00257	CcSEcCtD
Neostigmine—Insomnia—Capecitabine—colon cancer	0.000211	0.00256	CcSEcCtD
Neostigmine—Rash—Fluorouracil—colon cancer	0.00021	0.00255	CcSEcCtD
Neostigmine—Dermatitis—Fluorouracil—colon cancer	0.00021	0.00255	CcSEcCtD
Neostigmine—Headache—Fluorouracil—colon cancer	0.000209	0.00254	CcSEcCtD
Neostigmine—Dyspnoea—Capecitabine—colon cancer	0.000208	0.00252	CcSEcCtD
Neostigmine—Nausea—Irinotecan—colon cancer	0.000207	0.00251	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Capecitabine—colon cancer	0.000201	0.00244	CcSEcCtD
Neostigmine—Nausea—Fluorouracil—colon cancer	0.000198	0.0024	CcSEcCtD
Neostigmine—Gastrointestinal pain—Capecitabine—colon cancer	0.000191	0.00231	CcSEcCtD
Neostigmine—Urticaria—Capecitabine—colon cancer	0.000185	0.00225	CcSEcCtD
Neostigmine—Abdominal pain—Capecitabine—colon cancer	0.000184	0.00224	CcSEcCtD
Neostigmine—Convulsion—Methotrexate—colon cancer	0.000184	0.00224	CcSEcCtD
Neostigmine—Arthralgia—Methotrexate—colon cancer	0.000181	0.0022	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.00018	0.00218	CcSEcCtD
Neostigmine—Anaphylactic shock—Methotrexate—colon cancer	0.000174	0.00211	CcSEcCtD
Neostigmine—Hypersensitivity—Capecitabine—colon cancer	0.000172	0.00208	CcSEcCtD
Neostigmine—Nervous system disorder—Methotrexate—colon cancer	0.00017	0.00207	CcSEcCtD
Neostigmine—Skin disorder—Methotrexate—colon cancer	0.000169	0.00205	CcSEcCtD
Neostigmine—Hyperhidrosis—Methotrexate—colon cancer	0.000168	0.00204	CcSEcCtD
Neostigmine—Asthenia—Capecitabine—colon cancer	0.000167	0.00203	CcSEcCtD
Neostigmine—Pruritus—Capecitabine—colon cancer	0.000165	0.002	CcSEcCtD
Neostigmine—Hypotension—Methotrexate—colon cancer	0.000162	0.00197	CcSEcCtD
Neostigmine—Diarrhoea—Capecitabine—colon cancer	0.00016	0.00194	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000158	0.00192	CcSEcCtD
Neostigmine—Insomnia—Methotrexate—colon cancer	0.000157	0.0019	CcSEcCtD
Neostigmine—Dyspnoea—Methotrexate—colon cancer	0.000155	0.00188	CcSEcCtD
Neostigmine—Somnolence—Methotrexate—colon cancer	0.000154	0.00187	CcSEcCtD
Neostigmine—Dizziness—Capecitabine—colon cancer	0.000154	0.00187	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Methotrexate—colon cancer	0.00015	0.00182	CcSEcCtD
Neostigmine—Vomiting—Capecitabine—colon cancer	0.000148	0.0018	CcSEcCtD
Neostigmine—Rash—Capecitabine—colon cancer	0.000147	0.00178	CcSEcCtD
Neostigmine—Dermatitis—Capecitabine—colon cancer	0.000147	0.00178	CcSEcCtD
Neostigmine—Headache—Capecitabine—colon cancer	0.000146	0.00177	CcSEcCtD
Neostigmine—Gastrointestinal pain—Methotrexate—colon cancer	0.000142	0.00172	CcSEcCtD
Neostigmine—Nausea—Capecitabine—colon cancer	0.000139	0.00168	CcSEcCtD
Neostigmine—Urticaria—Methotrexate—colon cancer	0.000138	0.00167	CcSEcCtD
Neostigmine—Abdominal pain—Methotrexate—colon cancer	0.000137	0.00166	CcSEcCtD
Neostigmine—Hypersensitivity—Methotrexate—colon cancer	0.000128	0.00155	CcSEcCtD
Neostigmine—Asthenia—Methotrexate—colon cancer	0.000125	0.00151	CcSEcCtD
Neostigmine—Pruritus—Methotrexate—colon cancer	0.000123	0.00149	CcSEcCtD
Neostigmine—Diarrhoea—Methotrexate—colon cancer	0.000119	0.00144	CcSEcCtD
Neostigmine—Dizziness—Methotrexate—colon cancer	0.000115	0.00139	CcSEcCtD
Neostigmine—Vomiting—Methotrexate—colon cancer	0.00011	0.00134	CcSEcCtD
Neostigmine—Rash—Methotrexate—colon cancer	0.000109	0.00133	CcSEcCtD
Neostigmine—Dermatitis—Methotrexate—colon cancer	0.000109	0.00133	CcSEcCtD
Neostigmine—Headache—Methotrexate—colon cancer	0.000109	0.00132	CcSEcCtD
Neostigmine—Nausea—Methotrexate—colon cancer	0.000103	0.00125	CcSEcCtD
